Scholar IQ
Try ScholarIQ free
About the database
On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Nanoparticle-Based Drug Delivery

TopicLeading institutions, researchers & key papers

Nanoparticle-Based Drug Delivery is a topic indexed in ScholarIQ from OpenAlex.

What is known about Nanoparticle-Based Drug Delivery?

ScholarIQrecord summary

This cluster of papers focuses on the development and application of nanoparticle-based drug delivery systems, particularly for cancer therapy. It covers topics such as nanocarriers, surface engineering of nanoparticles, magnetic nanoparticles, tumor targeting, polymeric nanoparticles, and the enhanced permeability and retention (EPR) effect. The research explores the synthesis, functionalization, and biomedical applications of various types of nanoparticles for drug delivery.

How many works does Nanoparticle-Based Drug Delivery have?

ScholarIQindexed works

Nanoparticle-Based Drug Delivery has 228 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

What is the OpenAlex record for Nanoparticle-Based Drug Delivery?

ScholarIQopenalex

The OpenAlex for Nanoparticle-Based Drug Delivery is on the source record.

What are the most-cited papers on Nanoparticle-Based Drug Delivery?

ScholarIQmost cited works
Nanomedicine—Challenge and Perspectives
Kristina Riehemann, Stefan W. Schneider, Thomas A. Luger, Biana Godin, Mauro Ferrari, Harald Fuchs
Angewandte Chemie International Edition. 20091,292 CitationsOPEN ACCESS
The Shape Effect of Mesoporous Silica Nanoparticles on Biodistribution, Clearance, and Biocompatibility <i>in Vivo</i>
Xinglu Huang, Linlin Li, Tianlong Liu, Nanjing Hao, Huiyu Liu, Dong Chen, Fangqiong Tang
ACS Nano. 2011911 Citations
Impact of Silica Nanoparticle Design on Cellular Toxicity and Hemolytic Activity
Yu Tian, Alexander Malugin, Hamidreza Ghandehari
ACS Nano. 2011659 CitationsOPEN ACCESS
Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors
Qin Dai, Stefan Wilhelm, Ding Ding, Abdullah M. Syed, Shrey Sindhwani, Yuwei Zhang, Yih Yang Chen, Presley MacMillan, Warren C. W. Chan
ACS Nano. 2018653 Citations
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby, José Baselga, Yvonne Shao, Ulrik B. Nielsen, James D. Marks, Dan H. Moore, Demetrios Papahadjopoulos, Christopher C. Benz
PubMed. 2002648 CitationsOPEN ACCESS

Where is Nanoparticle-Based Drug Delivery research published, and who funds it?

ScholarIQvenues & funding sources

TOP FUNDERS

National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock

How much of the research on Nanoparticle-Based Drug Delivery is open access?

ScholarIQopen access share
60%OPEN ACCESS
Gold
7%
Green
20%
Hybrid
27%
Bronze
7%
Closed
40%

Related on ScholarIQ

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
Paper
Nanomedicine—Challenge and Perspectives
Paper
The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles
Paper
A review on phospholipids and their main applications in drug delivery systems
Paper
The Shape Effect of Mesoporous Silica Nanoparticles on Biodistribution, Clearance, and Biocompatibility <i>in Vivo</i>
Paper
Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies
Paper
470M+ articles · 14-day free trial